These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 15536360)
1. [Which chemotherapy for small cell lung cancers?]. Lebeau B Rev Pneumol Clin; 2004 Nov; 60(5 Pt 2):3S86-90. PubMed ID: 15536360 [TBL] [Abstract][Full Text] [Related]
2. [The effect of chemo-radiotherapy on the remission and survival in patients with limited stage small cell lung cancer]. Bozóky G; Ruby E; Góhér I; Gábor G; Mohos A; Lengyel M Orv Hetil; 2005 Jul; 146(27):1433-8. PubMed ID: 16089103 [TBL] [Abstract][Full Text] [Related]
3. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial. Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596 [TBL] [Abstract][Full Text] [Related]
4. [Modalities of radiotherapy in small cell lung cancer: thoracic radiotherapy and prophylactic cerebral irradiation]. Le Péchoux C; Dhermain F; Bretel JJ; Laplanche A; Dunant A; Tarayre M; Ruffié P; Le Chevalier T Rev Pneumol Clin; 2004 Nov; 60(5 Pt 2):3S91-103. PubMed ID: 15536361 [TBL] [Abstract][Full Text] [Related]
5. [Perspectives on chemotherapy of cancer of the bronchi]. Chauvergne J; Chomy P Rev Mal Respir; 1989; 6(5):409-16. PubMed ID: 2557652 [TBL] [Abstract][Full Text] [Related]
6. Accelerated hyperfractionated radiotherapy and concomitant chemotherapy in small cell lung cancer limited-disease. Dose response, feasibility and outcome for patients treated in western Sweden, 1998-2004. Hallqvist A; Rylander H; Björk-Eriksson T; Nyman J Acta Oncol; 2007; 46(7):969-74. PubMed ID: 17851846 [TBL] [Abstract][Full Text] [Related]
7. [The role of radiotherapy in the management of patients with small cell lung cancer]. Daveau C; Le Péchoux C; Besse B; Ferreira I; Amarouch A; Vicenzi L; Elloumi F; Roberti E; Bretel JJ Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S171-9. PubMed ID: 18235411 [TBL] [Abstract][Full Text] [Related]
8. SCLC extensive disease--treatment guidance by extent or/and biology of response? Eckert F; Müller AC Radiat Oncol; 2008 Oct; 3():33. PubMed ID: 18831728 [TBL] [Abstract][Full Text] [Related]
9. [Multimodal therapy of small cell and non-small cell lung carcinoma]. Serke M; Kollmeier J Dtsch Med Wochenschr; 2007 Jun; 132(22):1221-4. PubMed ID: 17520508 [TBL] [Abstract][Full Text] [Related]
11. Progress and pitfalls in small-cell lung cancer. Kalemkerian GP Oncology (Williston Park); 2008 Nov; 22(13):1498-500, 1506. PubMed ID: 19227572 [No Abstract] [Full Text] [Related]
12. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. Spiro SG; James LE; Rudd RM; Trask CW; Tobias JS; Snee M; Gilligan D; Murray PA; Ruiz de Elvira MC; O'Donnell KM; Gower NH; Harper PG; Hackshaw AK; J Clin Oncol; 2006 Aug; 24(24):3823-30. PubMed ID: 16921033 [TBL] [Abstract][Full Text] [Related]
13. Topotecan in the treatment of recurrent small cell lung cancer: an update. Ardizzoni A Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145 [TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy in cancer of the lung]. Gütz S MMW Fortschr Med; 2006 Jun; 148(22):33-4. PubMed ID: 16821578 [TBL] [Abstract][Full Text] [Related]
15. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. Brock MV; Hooker CM; Syphard JE; Westra W; Xu L; Alberg AJ; Mason D; Baylin SB; Herman JG; Yung RC; Brahmer J; Rudin CM; Ettinger DS; Yang SC J Thorac Cardiovasc Surg; 2005 Jan; 129(1):64-72. PubMed ID: 15632826 [TBL] [Abstract][Full Text] [Related]
16. [Small cell lung cancer (CPC). Second line treatment]. Lebeau B Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S205-16S208. PubMed ID: 17268359 [TBL] [Abstract][Full Text] [Related]
17. [The place for therapeutic intensification in small cell lung cancer]. Corne F; Thiberville L Rev Pneumol Clin; 2004 Nov; 60(5 Pt 2):3S104-9. PubMed ID: 15536362 [TBL] [Abstract][Full Text] [Related]
18. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S; Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326 [TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach. Cetingöz R; Cetinayak HO; Sen RC; Demiral AN; Akkoçlu A; Osma E; Kargi A; Oztop I; Onen A; Kinay M; J BUON; 2006; 11(1):31-7. PubMed ID: 17318949 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Schmittel A; Knödler M; Hortig P; Schulze K; Thiel E; Keilholz U Lung Cancer; 2007 Jan; 55(1):109-13. PubMed ID: 17097191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]